Results 161 to 170 of about 156,694 (295)

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples   +10 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Do Brain Extracellular Fluid Concentrations Predict PET‐Inferred Receptor Occupancy in Human CNS? A Mechanistic Model‐Based Analysis of Dopamine D2 Receptor Ligands

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
A mechanistic CNS PBPK model framework was applied to eight antipsychotic D2 receptor ligands, comparing brain extracellular fluid (brainECF) and brain cell membrane (brainM) as biophase for predicting human receptor occupancy compared against PET neuroimaging data. BrainM concentrations showed improved agreement with PET‐derived receptor occupancy for
Divakar Budda   +2 more
wiley   +1 more source

Socioeconomic inequalities in functional ageing trajectories in England and Canada: A comparative longitudinal cohort study. [PDF]

open access: yesPLoS Med
Schrempft S   +7 more
europepmc   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova   +9 more
wiley   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao   +5 more
wiley   +1 more source

Dynamic frailty exposure and cognitive aging trajectories: A multicohort study. [PDF]

open access: yesAlzheimers Dement
Wang X   +7 more
europepmc   +1 more source

Structural Validity of a Short Form of the Eating Disorder Examination Questionnaire in Adolescents Diagnosed With an Eating Disorder

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This study aimed to assess the structural validity and readability of a brief 7‐item version of the Eating Disorder Examination Questionnaire (the EDE‐Q7) among adolescents. Method Latent variable analysis was used in a sample of 263 adolescents (age range = 13–17.99y) diagnosed with an eating disorder and recruited from treatment ...
Paul E. Jenkins   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy